European Journal of Cancer Oncology
Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC
The publisher did not provide an abstract — full text is available via the link below.
European Journal of Cancer Oncology
The publisher did not provide an abstract — full text is available via the link below.